Skip to main content
Erschienen in: HNO 11/2012

01.11.2012 | Leitthema

Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren

Highlights vom ASCO-Meeting 2012

verfasst von: Dr. S. Laban, V. Zielinski, C.-J. Busch, A. Münscher, P. Schafhausen, S. Tribius, R. Knecht

Erschienen in: HNO | Ausgabe 11/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die primäre Radiochemotherapie wird in konkomitanter und sequenzieller Form in der Therapie von Kopf-Hals-Tumoren zunehmend verwendet. Beim jährlichen Meeting der American Society of Clinical Oncology 2012 wurden zahlreiche Studien zu diesem Thema vorgestellt. Eine Auswahl dieser Studien wird in diesem Artikel vorgestellt. Unter anderem werden Ergebnisse mehrerer Phase-III-Studien – auch über den lang erwarteten Vergleich von Induktionschemotherapie und konkomitanter Radiochemotherapie – präsentiert.
Literatur
1.
Zurück zum Zitat Ang K, Zhang Q, Wheeler RH et al (2010) A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. ASCO Meeting Abstracts 28:5507 Ang K, Zhang Q, Wheeler RH et al (2010) A phase III trial (RTOG 0129) of two radiation-cisplatin regimens for head and neck carcinomas (HNC): impact of radiation and cisplatin intensity on outcome. ASCO Meeting Abstracts 28:5507
2.
Zurück zum Zitat Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts 29:5500 Ang KK, Zhang QE, Rosenthal DI et al (2011) A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). ASCO Meeting Abstracts 29:5500
3.
Zurück zum Zitat Austin M, Schmidt R, Parvathaneni U et al (2012) Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. ASCO Meeting Abstracts 30:5515 Austin M, Schmidt R, Parvathaneni U et al (2012) Expression of p16, ERCC1, and EGFR amplification as predictors of responsiveness of locally advanced squamous cell carcinomas of head and neck (SCCHN) to cisplatin, radiotherapy, and erlotinib: a phase II randomized trial. ASCO Meeting Abstracts 30:5515
4.
Zurück zum Zitat Budach V, Cho C-H, Sedlmaier B et al (2012) Five years‘ results of the German ARO 04–01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. ASCO Meeting Abstracts 30:5512 Budach V, Cho C-H, Sedlmaier B et al (2012) Five years‘ results of the German ARO 04–01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer. ASCO Meeting Abstracts 30:5512
5.
Zurück zum Zitat Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRef Budach V, Stuschke M, Budach W et al (2005) Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95–06 Prospective Randomized Trial. J Clin Oncol 23:1125–1135PubMedCrossRef
6.
Zurück zum Zitat Cohen Eew, Karrison T, Kocherginsky M et al (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5500 Cohen Eew, Karrison T, Kocherginsky M et al (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5500
7.
Zurück zum Zitat Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRef Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098PubMedCrossRef
8.
Zurück zum Zitat Ghi MG, Paccagnella A, Ferrari D et al (2012) Cetuximab/radiotherapy (CET+ RT) versus concomitant chemoradiotherapy (cCHT+ RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 × 2 factorial, phase II-III study (NCT01086826). ASCO Meeting Abstracts 30:5513 Ghi MG, Paccagnella A, Ferrari D et al (2012) Cetuximab/radiotherapy (CET+ RT) versus concomitant chemoradiotherapy (cCHT+ RT) with or without induction docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head and neck squamous cell carcinoma (LASCCHN): Preliminary results on toxicity of a randomized, 2 × 2 factorial, phase II-III study (NCT01086826). ASCO Meeting Abstracts 30:5513
9.
Zurück zum Zitat Gillison Ml, Zhang Q, Jordan R et al (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102–2111PubMedCrossRef Gillison Ml, Zhang Q, Jordan R et al (2012) Tobacco smoking and increased risk of death and progression for patients with p16-positive and p16-negative oropharyngeal cancer. J Clin Oncol 30:2102–2111PubMedCrossRef
10.
Zurück zum Zitat Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). ASCO Meeting Abstracts 30:5502 Giralt J, Fortin A, Mesia R et al (2012) A phase II, randomized trial (CONCERT-1) of chemoradiotherapy (CRT) with or without panitumumab (pmab) in patients (pts) with unresected, locally advanced squamous cell carcinoma of the head and neck (LASCCHN). ASCO Meeting Abstracts 30:5502
11.
Zurück zum Zitat Haddad RI, Rabinowits G, Tishler RB et al (2012) The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). ASCO Meeting Abstracts 30:5501 Haddad RI, Rabinowits G, Tishler RB et al (2012) The PARADIGM trial: a phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LANHC). ASCO Meeting Abstracts 30:5501
12.
Zurück zum Zitat Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159PubMedCrossRef Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153–159PubMedCrossRef
13.
Zurück zum Zitat Martins R, Parvathaneni U, Sharma AK et al (2012) Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5503 Martins R, Parvathaneni U, Sharma AK et al (2012) Randomized phase II trial of cisplatin and radiotherapy with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting Abstracts 30:5503
14.
Zurück zum Zitat Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715PubMedCrossRef Posner MR, Hershock DM, Blajman CR et al (2007) Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705–1715PubMedCrossRef
15.
Zurück zum Zitat Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (−) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. ASCO Meeting Abstracts 30:5504 Stoehlmacher-Williams J, Villanueva C, Foa P et al (2012) Safety and efficacy of panitumumab (pmab) in HPV-positive (+) and HPV-negative (−) recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): analysis of the global phase III SPECTRUM trial. ASCO Meeting Abstracts 30:5504
16.
Zurück zum Zitat Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704PubMedCrossRef Vermorken JB, Remenar E, Van Herpen C et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695–1704PubMedCrossRef
17.
Zurück zum Zitat Wuthrick EJ, Zhang Q, Machtay M et al (2012) The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): an analysis of RTOG 0129. ASCO Meeting Abstracts 30:5530 Wuthrick EJ, Zhang Q, Machtay M et al (2012) The influence of institutional head and neck cancer (HNC) clinical trial accrual on overall survival (OS): an analysis of RTOG 0129. ASCO Meeting Abstracts 30:5530
Metadaten
Titel
Die wichtigsten Studienergebnisse der primären Radiochemotherapie von Kopf-Hals-Tumoren
Highlights vom ASCO-Meeting 2012
verfasst von
Dr. S. Laban
V. Zielinski
C.-J. Busch
A. Münscher
P. Schafhausen
S. Tribius
R. Knecht
Publikationsdatum
01.11.2012
Verlag
Springer-Verlag
Erschienen in
HNO / Ausgabe 11/2012
Print ISSN: 0017-6192
Elektronische ISSN: 1433-0458
DOI
https://doi.org/10.1007/s00106-012-2595-x

Weitere Artikel der Ausgabe 11/2012

HNO 11/2012 Zur Ausgabe

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.